Effectiveness, safety, and tolerability of delayed dexamethasone, rituximab, and cyclophosphamide as first-line treatment in patients with Waldenström macroglobulinemia: data from the Sicilian Myeloma Network

BackgroundWaldenström macroglobulinemia (WM) is a rare and indolent B-cell lymphoproliferative disorder with greater incidence in elderly patients where a precise algorithm of initial therapy is still not clear. Immunochemotherapy regimen consisting of dexamethasone, rituximab, and oral cyclophospha...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Vittorio Del Fabro, Uros Markovic, Sara Frazzetto, Roberta Sciortino, Claudia Bellofiore, Mary Ann Di Giorgio, Valerio Leotta, Anna Bulla, Angelo Curto Pelle, Federica Elia, Donato Mannina, Ugo Consoli, Giuseppe Mineo, Cesarina Giallongo, Alessandra Romano, Francesco Di Raimondo, Concetta Conticello
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2024-06-01
coleção:	Frontiers in Hematology
Assuntos:	Waldenström macroglobulinemia first line treatment DRC regimen four-week cycle safety
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/frhem.2024.1425677/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!